Pharma BD Deal Intelligence

Genzyme General (Genzyme Corporation) / GelTex Pharmaceuticals Inc.

2000 · Acquisition/Merger · $1.0B · Complete

Announcement Sentiment

Positive

Genzyme General acquired GelTex Pharmaceuticals in a stock deal valued at ~$1.0B (based on 21.4M GelTex shares and Genzyme's $65.31 close on Sep 8). Brought Renagel and WelChol marketed products plus a polymer drug platform. Closed Dec 14, 2000.

Did it work? Outcome assessment

Strategic verdict

Achieved Stated Rationale

Financial impact

Accretive

Pipeline outcome

Assets Advanced

Assessment window: 15yr post-close.

Key facts

Announced Sep 11, 2000
Closed Dec 14, 2000
Deal value $1.0B
Deal type Acquisition/Merger
Therapeutic area Hyperphosphatemia in ESRD; hypercholesterolemia
Indications Hyperphosphatemia in ESRD; hypercholesterolemia
Key assets Renagel (sevelamer hydrochloride), WelChol (colesevelam)
Mechanism Phosphate binder polymer; bile-acid sequestrant polymer

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals